Cytodigm is focused on developing next-generation therapeutics by leveraging its proprietary technologies to enhance targetability and delivery efficiency while minimizing immunogenicity and toxicity. We are advancing our proprietary lipid-based and polymer nanoparticle platforms to deliver nucleic acids and other therapeutic payloads for in vivo cell, gene, and immune therapy and to target solid tumors.
Cytofinity™ and Sigfinity™ are Cytodigm’s lipid-based nanoparticle platforms designed to deliver nucleic acid therapeutics with improved precision and reduced side effects. These platforms are key components of our strategy to enhance in vivo delivery to various organs and cells.
Zetafinity® is a clinically proven polymer nanoparticle delivery system used by Cytodigm to enable the treatment of solid tumors. This technology enhances the delivery of therapeutic agents directly to immune cells and tumor microenvironment (TME), improving treatment efficacy and safety.
Cytodigm aims to advance its technology to clinical proof of concept, leveraging platform value through collaborations with other biopharmaceutical companies and out-licensing for various disease indications. This approach enables us to maximize the impact and reach of our innovations.
Cytodigm is open to collaborations with biopharmaceutical companies interested in leveraging our innovative nanoparticle platforms for diverse therapeutic applications. To explore partnership opportunities, please contact us through our Contact Page for more information.
Established in 2022, Cytodigm has rapidly developed its unique nanoparticle delivery platforms and is actively pursuing clinical proof of concept for its technologies while exploring strategic partnerships to expand its reach in the therapeutic landscape.
Cytofinity™ LNPs comprise gangliosides that bear sialic acid (SA) entities in the molecules. Sialic acid binds Siglecs, or sialic acid-binding immunoglobulin-like lectins, which are expressed on the surface of many types of cells. Binding cell-surface Siglecs can lead to receptor-mediated endocytosis, thus facilitating cell-targeting and intracellular delivery.
